Shares of Doximity upgraded to buy, price target set on involvement of uptick By Investing.com
On Friday, Needham raised its rating on shares of Doximity Inc (NYSE: ) to Buy, citing strong momentum with large customers and new product innovations. The firm set a $38.00 price objective on the company’s stock.
This development comes as Doximity, a digital platform for medical professionals, has shown significant improvement in engagement with large clients, particularly within the pharmaceutical industry. This engagement contributed to a positive first quarter and resulted in an increase in the outlook for fiscal year 2025.
Doximity's new products, such as Point of Care and Formulary products, grew significantly, exceeding 70%. These innovations are believed to contribute to the wallet share gains. Additionally, the client's portal, currently used for purchasing and reporting, contributed to driving purchasing decisions and led to higher than expected sales levels in the first quarter.
The improved visibility in Doximity's fiscal year guidance, coupled with increased revenue starting to contribute to financial performance, suggests the company may be on track to outperform expectations. This return to rhythm and increasing pattern was a key factor in Needham's decision to upgrade the stock.
Needham highlights Doximity's current valuation of 18 times its fiscal 2026 free cash flow as an attractive entry point for investors. The company expects that the company can see an increase of up to 10 percent in the near term from the levels seen in the first quarter.
In other recent news, Doximity Inc. it has been the focus of several analyst firms following its strong financial performance. The company exceeded its fourth-quarter revenue guidance, reporting $118 million and achieving annual growth of 13%, peaking at $475 million in fiscal 2024. Q4.
Evercore ISI raised Doximity's price target, citing a strong sales season and the success of new products. However, Wells Fargo downgraded shares of Doximity, moving the rating from Equal Weight to Underweight, indicating concern about the company's growth trajectory. Barclays maintained an Equalweight rating on Doximity shares, noting the positive aspects of the latest earnings report and share buyback plan.
Truist Securities revised their outlook on Doximity, upping their price target for the stock to $31.00 from $29.00 previously. The company continues to hold neutral on the stock. This latest development reflects the mixed reaction from investors and analysts to Doximity's latest earnings report and financial performance.
InvestingPro Insights
Following a positive outlook from Needham, InvestingPro's statistics also shed light on the financial health and growth of Doximity Inc (NYSE:DOCS). A company's aggressive stock buyback strategy, as highlighted in one of InvestingPro's tips, is a strong sign of management's commitment to the company's value. Additionally, Doximity's gross profit margin of 89.34% for the last twelve months from Q4 2024 underscores its efficiency in generating revenue relative to expenses.
In addition, the company's strong financial position, with more cash than debt on its balance sheet, provides financial stability and flexibility, which is essential for sustaining growth and changing economic conditions. This is in line with the fact that Doximity does not pay dividends, allowing it to reinvest earnings back into the company to drive new projects and market expansion.
InvestingPro Data reports a market capitalization of $4.76 billion, and a forward P/E ratio of 30.65, which, when paired with a PEG ratio of 0.9, suggests the stock may be trading at a fair price relative to its earnings growth. Investors and analysts alike can find more information and tips, including 6 more updated earnings forecasts for the future, on Doximity's InvestingPro forum at
This article was created with the support of AI and reviewed by an editor. For more information see our T&C.
